**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 77042

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Role of sex on psychological distress, quality of life, and coping of patients with advanced colorectal and non-colorectal cancer**

Pacheco-Barcia V *et al*. Sex role in advanced gastrointestinal cancer

Vilma Pacheco-Barcia, David Gomez, Berta Obispo, Luka Mihic Gongora, Raquel Hernandez San Gil, Patricia Cruz-Castellanos, Mireia Gil-Raga, Vicente Villalba, Ismael Ghanem, Paula Jimenez-Fonseca, Caterina Calderon

**Vilma Pacheco-Barcia,** Department of Medical Oncology, School of Medicine, Alcala University (UAH), Hospital Central de la Defensa Gómez Ulla, Madrid 28047, Spain

**David Gomez,** Department of Medical Oncology, Hospital Universitario de Navarra, Pamplona 31008, Spain

**Berta Obispo,** Department of Medical Oncology, Hospital Universitario Infanta Leonor, Madrid 28031, Spain

**Luka Mihic Gongora,** Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo 33011, Spain

**Raquel Hernandez San Gil,** Department of Medical Oncology, Hospital Universitario de Canarias, Tenerife 38320, Spain

**Patricia Cruz-Castellanos, Ismael Ghanem,** Department of Medical Oncology, Hospital Universitario La Paz, Madrid 28046, Spain

**Mireia Gil-Raga,** Department of Medical Oncology, Hospital General Universitario de Valencia, CIBERONC, Valencia 46014, Spain

**Vicente Villalba,** Department of Clinical Psychology and Psychobiology, Faculty of Psychology, University of Barcelona, Barcelona 08007, Spain

**Paula Jimenez-Fonseca,** Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, Oviedo 33007, Spain

**Caterina Calderon,** Department of Clinical Psychology and Psychobiology, University of Barcelona, Barcelona 08007, Spain

**Author contributions:** Pacheco-Barcia V, Calderon C, and Jimenez-Fonseca P developed the project, analyzed the data, anddrafted themanuscript; The other authors recruited patients and provided clinical information, comments, andimprovements to the manuscript; All authors participated in the interpretation and discussion of dataand the critical review of the manuscript.

**Supported by** The FSEOM (Spanish Society of Medical Oncology Foundation) grant for Projects of the Collaborative Groups in 2018 and by an Astra Zeneca grant, No. ES2020-1939.

**Corresponding author: Vilma Pacheco-Barcia, MD, MSc, PhD, Associate Professor, Doctor,** Department of Medical Oncology, School of Medicine, Alcala University (UAH), Hospital Central de la Defensa Gómez Ulla, Glorieta del Ejercito 1, Madrid 28047, Spain. vilmapbarcia@yahoo.es

**Received:** April 25, 2022

**Revised:** May 24, 2022

**Accepted:** **August 25, 2022**

**Published online:**

**Abstract**

BACKGROUND

Patients with advanced gastrointestinal cancer must cope with the negative effects of cancer and complications.

AIM

To evaluate psychological distress, quality of life, and coping strategies in patients with advanced colorectal cancer compared to non-colorectal cancer based on sex.

METHODS

A prospective, transversal, multicenter study was conducted in 203 patients; 101 (50%) had a colorectal and 102 (50%) had digestive, non-colorectal advanced cancer. Participants completed questionnaires evaluating psychological distress (Brief Symptom Inventory-18), quality of life (EORTC QLQ-C30), and coping strategies (Mini-Mental Adjustment to Cancer) before starting systemic cancer treatment.

RESULTS

The study included 42.4% women. Women exhibited more depressive symptoms, anxiety, functional limitations, and anxious preoccupation than men. Patients with non-colorectal digestive cancer and women showed more somatization and physical symptoms than subjects with colorectal cancer and men. Men with colorectal cancer reported the best health status.

CONCLUSION

The degree of disease acceptance in gastrointestinal malignancies may depend on sex and location of the primary digestive neoplasm. Future interventions should specifically address sex and tumor site differences in individuals with advanced digestive cancer.

**Key Words:** Anxiety; Colorectal cancer; Depression; Gastrointestinal cancer; Sex

Pacheco-Barcia V, Gomez D, Obispo B, Mihic Gongora L, Hernandez San Gil R, Cruz-Castellanos P, Gil-Raga M, Villalba V, Ghanem I, Jimenez-Fonseca P, Calderon C. Role of sex on psychological distress, quality of life, and coping of patients with advanced colorectal and non-colorectal cancer. *World J Gastrointest Oncol* 2022; In press

**Core Tip:** Patients with advanced gastrointestinal cancer must cope with the negative effects of cancer and complications. However, data on psychological distress, quality of life, and coping strategies in patients with advanced colorectal cancer compared to non-colorectal cancer based on sex is lacking. This was a multicenter study conducted in 203 patients that completed questionnaires evaluating psychological distress, quality of life, and coping strategies before starting systemic cancer treatment. Based on these data, the degree of disease acceptance in gastrointestinal malignancies may depend on sex and location of the primary digestive neoplasm.

**INTRODUCTION**

***Background***

Gastrointestinal cancers are among the most prevalent both worldwide and in Spain[1,2]. Colorectal cancer is the most frequent neoplasm in Spain in both sexes[2] with close to 65% survival at 5 years, although this rate declines in metastatic stages and in unresectable cancers[3]. The most common non-colorectal digestive cancers are pancreatic, gastric, and hepatocellular carcinoma, which are associated with a worse prognosis than colorectal cancer with a 5-year survival rate of < 5 years in the advanced scenery.

Individuals with advanced gastrointestinal cancer must face the negative effects (pain, malnutrition) and tumor-related complications (intestinal obstruction or hemorrhage). Advances made in recent years in anticancer treatment modalities to fight these cancers have managed to extend overall survival (OS) and control physical symptoms. Meanwhile, emotional distress in these cases has been correlated with diminished quality of life and with a negative impact on treatment compliance[4,5] and on oncological outcomes[6,7]. Furthermore, psychological suffering can aggravate vomiting and other side effects of systemic antineoplastic treatment and of the cancer itself[8-10]. For its part, the type of cancer and surgery can affect the emotional distress and quality of life in individuals with a gastrointestinal neoplasm. In a Spanish prospective series, people with pancreatic-biliary cancer expressed more somatic complaints, depression, and anguish than those with colorectal cancer, whereas participants with gastroesophageal neoplasms suffered higher rates of depression, psychological distress, and hopelessness than those with colorectal cancer[11].

The relevance of contemplating sex and its influence on study outcomes is stated in the SAGER guidelines (Sex and Gender Equity in Research) designed to inform authors in preparing their manuscripts[12,13]. Sex, understood as going beyond its biological concept (chromosomal assignment) and founded on the basis of the roles and relationships established throughout the person’s lifetime, is a sociodemographic variable that can give rise to differences in the evolution as well as the clinical and psychological aspects of cancer[14]. This is particularly relevant in cancers such as digestive neoplasms that have a higher incidence in men and in which there may be an underrepresentation of women who may experience a different evolution and coping style that call for specific approaches[15,16].

In the case of advanced gastroesophageal tumors, women have been seen to be less likely to receive systemic treatment with chemotherapy when the histology is adenocarcinoma with no difference among patients with squamous cell tumors. This impacts survival, in as much as men display increased OS in esophageal adenocarcinomas with no differences in survival rates by sex in cases of esophageal squamous cell carcinoma in some studies, while others attribute a higher incidence of cancers having an unfavorable and more aggressive histology among women[17-20]. As for pancreatic cancer, differences in the efficacy and toxicity of chemotherapy have been observed between men and women[21,22]. Women receiving FOLFIRINOX are older at the time of diagnosis and exhibit higher OS rates than men, despite requiring an earlier dose decrease due to early toxicity, which is possibly attributable to worse tolerance to systemic treatment. No study has investigated whether this poor tolerance is influenced by psychological factors[23].

Other clinical trials have revealed a trend toward higher progression-free survival and OS in women, although these findings were not statistically significant[23,24]. In individuals with localized colorectal cancer, a large-scale German study examined sex and found that the women were older than the men, had a more advanced stage at the time of diagnosis, and received a lower dose intensity of chemotherapy, despite having greater disease-free survival and OS[25]. The more advanced stage of disease among women might be due to the greater acceptance of endoscopic screening by men, among other reasons[26-28]. Therefore, women with digestive cancers are usually diagnosed at older ages than men and regardless of a lower rate of chemotherapy administration and greater toxicity in general, they display better survival rates without any study having been conducted to probe the cause behind such differences and whether psychological factors may play a role.

Three key psychological factors in cancer patients are psychological distress[6], quality of life[29-31], and coping[32,33]. Earlier studies have reported that up to 54% of people with colorectal cancer suffer anxiety and 27% suffer from depression[34-36] with higher incidences among women[37]. One study performed in subjects with gastrointestinal cancer in Spain reported that men with colorectal cancer have a worse quality of life, associated with physical performance and emotional and cognitive functioning[38]. Oppegaard *et al*[39] carried out a descriptive study focusing on sex differences in coping strategies and noted that women scored higher on positive reframing, religion, and instrumental support, while men scored higher for mood. Nevertheless, the question has never been studied as to whether these differences are due to the person’s biological sex or if there are sex characteristics (acquired) or other biopsychosocial variables that modulate coping, emotional stress, and quality of life.

***Objectives***

The aim of our study was to analyze whether there were differences between colorectal and non-colorectal digestive cancer in sociodemographic and/or clinical conditions and compared mental health status, quality of life, and coping between colorectal and non-colorectal digestive cancer patients depending on sex. We believe that these results may be useful to design specific preventive programs for each group.

**MATERIALS AND METHODS**

***Study design***

NEOetic is a multi-institutional (22 Spanish hospitals), prospective, observational study and is part of a cancer patient research program funded by the Spanish Society of Medical Oncology. The study was approved by the Ethics Committee of each institution and by the Spanish Agency of Medicines and Medical Devices (identification code: ES14042015).

***Participants***

The study was a cohort study, and participants were 18 years of age or older with unresectable, locally advanced, or metastatic cancer and were candidates for systemic antineoplastic treatment. For the purposes of this analysis, subjects with digestive cancers were regarded and grouped as being colorectal (colon and rectum) and non-colorectal digestive (esophagus, stomach, pancreas, biliary tract, liver, anal canal).

***Setting***

Patients were invited to participate in the study at the first visit with the oncologist where they were informed of the treatment alternatives for their cancer. Participation was voluntary, anonymous, and did not affect patient care. All patients included in the study signed an informed consent for their inclusion. The study was undertaken according to the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) guidelines[40].

We screened 245 patients; 203 were eligible for this analysis and 42 were excluded (10 failed to meet the inclusion criteria, 13 met the exclusion criteria, and 19 had incomplete data at the time of analysis).

***Variables and measures***

Demographic and clinical data (age, sex, marital status, educational level, employment status, tumor location and stage, and treatment) were obtained and updated by the medical oncologist directly from the patients and from their records. The oncologist explained the questionnaires to the participant who completed them at home during the 1st month following diagnosis of advanced disease and prior to starting cancer treatment. The questionnaires used are validated and are described below.

***Data sources/measurement***

The Brief Symptom Inventory consists of 18 items divided into three dimensions (somatization, depression, and anxiety) as well as a total score, the Global Severity Index, which summarizes the respondent’s overall emotional adjustment or psychological distress over the last 7 d[41]. Each item is rated on a 5-point Likert scale and Cronbach’s alpha ranged between 0.81 and 0.90[42].

The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) contains 30 items comprising four subscales: functioning, symptoms, health status, and global quality of life[43]. The response choices range from 1 (not at all) to 4 (very much), except for the health status scale, where responses range from 1 (very poor) to 7 (excellent). All scale scores are linearly transformed into a 0-100 scale. Higher scores on the functioning scales and global quality of life scale represent a higher level of functioning or quality of life. For the symptom scales, the higher the score, the greater the symptom burden. In this sample α = 0.85[44].

The Mini-Mental Adjustment to Cancer is a 29-item scale that assesses cancer-specific coping strategies as being adaptive (cognitive avoidance, fighting spirit, and fatalism) or maladaptive (helplessness and anxious preoccupation)[45]. When studying the psychometric properties of the Spanish translation of the scale, a 4-factor structure is found and used in this study; it includes helplessness, anxious preoccupation, and cognitive avoidance as well as a new subscale, positive attitude, that combines fighting spirit and fatalism[46]. Each item is rated on a 4-point Likert scale and Cronbach’s alpha coefficients for each domain ranged from 0.62-0.88[46].

***Statistical analysis***

Descriptive statistics were used for demographic data and survey responses. Absolute frequencies were used for categorical data and mean and standard deviation for quantitative data. Additional descriptive analyses were performed, grouping patients by cancer type. We conducted bivariate *χ*2 and *t* tests to examine differences between colorectal cancer and non-colorectal digestive cancer patients in terms of sociodemographic, clinical, and psychological characteristics.

A general linear model was created for each dependent variable (psychological distress, quality of life, and coping) with the different cancer type (colorectal and non-colorectal digestive); the effect of sex was probed, in addition to the interaction effect between sex and cancer type. All post-hoc tests were subjected to Bonferroni correction. All analyses were complemented with the corresponding effect size statistic. Reference values were established as 0.01, 0.06, and > 0.14 for small, medium, and large sizes, respectively, for the partial eta-square (ŋ2p). Statistics were generated using a standard statistical software package IBM SPSS Statistics for Windows, version 23.0 (IBM Corp., Armonk, NY, United States).

**RESULTS**

***Participants***

The study admitted 203 patients recruited during 2021. There were 101 (50%) colorectal cancer sufferers, and 102 (50%) had a non-colorectal digestive malignance.

***Descriptive data***

The sociodemographic and clinical characteristics of both groups are displayed in Table 1. Of the total study population, 115 (56.7%) were men and 88 (43.3%) were women. The percentage of men *vs* women in those with colorectal and non-colorectal digestive tract malignances was 60 (59.4%) to 41 (40.6%) and 55 (53.9%) to 47 (46.1%), respectively. The median age was 65.7 years (range: 34-88, standard deviation = 9.6).

***Outcome data***

Colorectal cancer patients tended to be younger than those with non-colorectal, gastrointestinal cancer (*P* = 0.028, λ = 0.081). Additionally, colorectal cancer patients had a better Eastern Cooperative Oncology Group performance status than non-colorectal digestive cancer patients, 34.7% *vs* 20.6%, respectively (*P* = 0.029, λ = 0.086). Most participants were married or partnered (86.6%) with children (82.2%) and had a primary level of education (55.2%). All subjects were either retired or unemployed.

Of the patients with non-colorectal digestive cancer, the most common primary tumor site was the pancreas (54.9%, *n* = 56), followed by the stomach (22.5%, *n* = 23), esophagus (8.8%, *n* = 9), biliary tract (6.9%, *n* = 7), liver (4.9%, *n* = 5), and anus (2%, *n* = 2). Individuals with colorectal cancer were diagnosed with metastatic disease more often than unresectable, locally advanced cancer (*P* = 0.001, λ = 0.218); biomarkers to guide treatment options were more often available in these subjects (*P* = 0.001, λ = 0.196), and most received combined, systemic treatment with chemotherapy and a targeted drug (*P* = 0.001, λ = 0.339). The estimated 18-mo survival rate was 86.1% in colorectal cancer patients compared to 7.8% in patients with non-colorectal digestive cancer (*P* = 0.001, λ = 0.776).

***Psychological distress***

The general linear model results indicated significant differences in the levels of somatization (F(1,202) = 5.0244, *P* = 0.026, η2p = 0.025), depression (F(1,202) = 15.747, *P* = 0.001, η2p = 0.073), and anxiety (F(1,202) = 19.697, *P* = 0.001, η2p = 0.090). The posthoc test showed significant differences in mean scores by sex, *i.e.* women manifested more depressive symptoms (η2p = 0.073) and anxiety (η2p = 0.061) than men. Patients with non-colorectal digestive cancer (η2p = 0.020) and women (η2p = 0.025) displayed more somatization than subjects with colorectal cancer and men. The model parameters and significant categories of each predicted variable are presented in Table 2 and Figure 1.

***Quality of life***

Again, the general linear model results revealed significant differences on the functional (F(1,202) = 19.697, *P* = 0.001, η2p = 0.090) and symptom (F(1,202) = 8.154, *P* = 0.005, η2p = 0.039) scales. The posthoc test indicated that women presented more functional limitations than men (ŋ2p = 0.090). Participants with non-colorectal, gastrointestinal cancer (η2p = 0.030) and women (η2p = 0.039) had more symptoms than those with colorectal cancer and who were men. The results revealed a significant effect of sex on symptom control. A statistically significant association between tumor type and sex in health status levels was observed, and men with colorectal cancer reported the best health status (η2p = 0.025) (Table 2 and Figure 1).

***Coping strategies***

In coping strategies, positive attitude and cognitive avoidance were the most widely used strategies by all patients included, and hopelessness was the least used (Table 2 and Figure 2). Differences were observed in the estimated mean scores for anxious preoccupation (F(1,202) = 6.722, *P* = 0.010, η2p = 0.033) and positive attitude (F(1,202) = 4.389, *P* = 0.037, η2p = 0.022). Post hoc tests showed that women presented more anxious preoccupation (η2p = 0.033) and less positive attitude (η2p = 0.022) than men.

**DISCUSSION**

***Key results***

In this study we analyzed the differences in emotional distress, quality of life, and coping by digestive tumor type and sex. Women displayed more depressive symptoms, anxiety, functional limitations, and anxious preoccupation than men. Individuals with non-colorectal digestive cancer and women exhibited more physical symptoms and somatization than patients with colorectal cancer and men, whereas men with colorectal cancer reported better health status. By type of cancer, participants with colorectal cancer are younger, treatment is more often adjusted by biomarkers, they receive more combined chemotherapy and a biological agent, their estimated survival is higher, and they have better general status at the time of diagnosis than subjects with non-colorectal digestive cancer.

***Interpretation***

As for coping strategy, women exhibited more anxious preoccupation and men exhibited positive attitude. These results might explain why women present more symptoms and worse functional status than men. Oppegaard *et al*[39] observed that women scored higher on denial, which has previously been associated with worse oncological outcomes, given the delay in seeking care, which in turn entails a diagnosis made at more advanced stages, with worse general status, and lower survival rates[47]. Furthermore, Oppegaard *et al*[39] demonstrated that women scored higher on self-distraction as a detachment coping strategy, which had already been associated with a decreased sense of meaning of life in both women and men with cancer[48].

In our study, women suffered more psychological distress in the form of anxiety and depression compared to men, and women with non-colorectal digestive cancer displayed more somatization than men and than women with colorectal cancer. Most studies have encountered similar results. Aminisani *et al*[49] evaluated psychological distress in a cohort of 303 colorectal cancer survivors from Iran. One-third of the study population presented depression and more than half of them exhibited anxiety; both conditions were more common among women than men. Sex differences in psychological distress have been reported by Gonzalez-Saenz de Tejada *et al*[50], revealing that men had less depression and anxiety. In The Netherlands, Braamse *et al*[51] found that women had higher levels of depression but not anxiety. Mols *et al*[30] observed that men suffered less anxiety and depression over time. Linden *et al*[52] examined anxiety and depression in a large cohort of oncological patients (*n* = 10153), including breast and gynecological cancer, and detected that women had more anxiety and depression than men, similar to our findings. Women have already been reported to exhibit greater acceptance of cancer of the reproductive organs compared to patients with gastrointestinal neoplasms[53]. Shapiro *et al*[54] published similar levels of depressive symptoms in individuals of both sexes with advanced cancer, and Goldzweig *et al*[15], in a cohort of 339 subjects with stage I-III colorecta cancer, reported greater psychological distress and impotence in men than in women, without knowing the reason for this disparity with respect to other studies. One of the most relevant points of our work is that it focuses specifically on gastrointestinal neoplasms and reveals that not only women (in general) but specifically those with non-colorectal digestive cancer are the ones who exhibit greater psychological distress.

Trinquinato *et al*[55] appraised quality of life in Brazilian patients with colorectal cancer undergoing chemotherapy and reported that chemotherapy negatively impacted men and women differentially. In their study, they found that cognitive function led to worse quality of life in men compared to women and that symptoms varied according to sex. Men had worse quality of life, due to sexual impotence and fecal incontinence, while in women, poor quality of life was associated with body image, abdominal pain, and dry mouth. Similarly, the women in our study had more functional limitations and more symptoms compared to men, with the corresponding impact of sex on the type of symptoms.

Individuals with advanced colorectal cancer have a better prognosis than those with non-colorectal digestive cancer[2], and better patient-perceived quality of life might correlate with better acceptance of the disease, given the better prognosis and the presence of fewer symptoms. In our study, the participants with non-colorectal digestive cancers had more somatization symptoms than those with colorectal cancer, which may be attributable to the unfavorable prognosis. In a cohort of 378 individuals with colorectal, gastric, and pancreatic cancer, Czerw *et al*[56] reported that those with colorectal cancer displayed an active behavior coping strategy compared to the subjects with non-colorectal cancer, who demonstrated a maladaptive coping behavior. In contrast, in our series, the strategies most widely used by the participants with advanced digestive tract cancers were positive attitude and cognitive avoidance, although the non-colorectal cancer group exhibited higher levels of helplessness, in line with outcomes observed by Czerw *et al*[56] in pancreatic cancer.

Colorectal cancer has the best prognosis among the main digestive tumors. However, neither the causes nor the prognostic differences in digestive cancers according to sex are well established. Colorectal cancer in women is located more often in the right colon than in men, which is a location associated with worse prognosis[57-59]. That being said, Schmuck *et al*[25] observed that the women included in a study of a cohort of people over 50 years of age had a better OS than men. The authors consider that these outcomes may have to do with the protective effect of women hormones against colorectal cancer, although there may be other causes for these prognostic disparities across sexes[60,61]. In a sample of 13391 patients from a Norwegian cancer registry, men with gastroesophageal adenocarcinoma were more often assigned to potentially curative treatment compared to the women and had higher 5-year survival rates[16]. Kim *et al*[21] detected greater survival in women with advanced pancreatic cancer with worse tolerance of chemotherapy that has been linked to less clearance of cytotoxic drugs, such as 5-fluorouracil[62] and irinotecan[63-65], and with greater toxicity in women compared to men[66].

***Generalisability***

There are no data concerning sex differences in cancer perception among patients with advanced gastrointestinal malignancies, and previous studies that included patients with metastatic colorectal cancer and non-colorectal digestive cancer have not reported specific data in this regard[56,67]. Women have been underrepresented in gastrointestinal cancer research, and men have been underrepresented in cancer-associated psychosocial assessment[68]. The relevance of assessing sex differences stems from the fact that men and women have specific social, psychological, and physical characteristics that might compromise coping strategies and perceptions of quality of life.

***Limitations***

The present study has several limitations. First, the underrepresentation of some non-colorectal digestive cancer subtypes and the heterogeneity of the data could bias the overall estimates. Second, the questionnaires were completed during the appointment prior to beginning antineoplastic treatment, which does not capture the variation of parameters over time nor the causal relationship between variables. Third, the study only included patients from Spain and advanced stage cancers; thus, these results should be confirmed in patients from other countries and with cancers of other stages.

**CONCLUSION**

In conclusion, this study has detected differences in psychological distress, quality of life, and coping with cancer between women and men and between patients with colorectal and non-colorectal digestive cancers. Women and patients with non-colorectal gastrointestinal tract malignances have more physical symptoms and somatization, and women suffer more psychological distress. These findings, if confirmed, suggest that sex and location of the primary digestive neoplasm should be considered in individualized communication with the patient to achieve a suitable approach to their psychological situation. Future studies should factor in sex and primary tumor site differences in advanced gastrointestinal cancer patients.

**ARTICLE HIGHLIGHTS**

***Research background***

Patients with advanced gastrointestinal cancer must cope with the negative effects of cancer and complications. Sex is a sociodemographic variable that can give rise to differences in the evolution as well as the clinical and psychological aspects of cancer.

***Research motivation***

To analyze whether there are differences between colorectal and non-colorectal digestive cancer in sociodemographic and/or clinical conditions and coping depending on sex.

***Research objectives***

To evaluate psychological distress, quality of life, and coping strategies in patients with advanced colorectal cancer compared to non-colorectal cancer based on sex.

***Research methods***

This was a multi-institutional prospective, observational study that evaluated patients with advanced digestive cancers; 203 patients were eligible for this analysis. Demographic and clinical data were obtained and the association between psychological distress, quality of life, and coping strategies and the role of sex and primary tumor site were analyzed.

***Research results***

Women exhibited more depressive symptoms, anxiety, functional limitations, and anxious preoccupation than men. Non-colorectal digestive cancer patients and women showed more somatization and physical symptoms than colorectal cancer patients and men.

***Research conclusions***

Disease acceptance in patients with advanced cancer of the digestive tract may be sex dependent.

***Research perspectives***

Future interventions should evaluate primary tumor site and sex differences in patients with gastrointestinal malignancies.

**ACKNOWLEDGEMENTS**

The authors thank the Bioethics Section of the Spanish Society of Medical Oncology (SEOM) for their contribution to this study, Priscilla Chase Duran for editing the manuscript, and Natalia Cateriano, Miguel Vaquero, and IRICOM S.A. for supporting the registry website. The authors are indebted to all patients as well as to NEOetic-SEOM centers and investigators who participated in this research and made it possible.

**REFERENCES**

1 **World Health Organization International Agency for Research on Cancer (IARC)**. Globocan 2020: estimated cancer incidence, mortality and prevalence worldwide in 2020. Available from: <https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf>

2 **World Health Organization International Agency for Research on Cancer (IARC)**. Globocan 2020: estimated cancer incidence, mortality and prevalence in Spain in 2020.. Available from: <https://gco.iarc.fr/today/data/factsheets/populations/724-spain-fact-sheets.pdf>

3 **National Cancer Institute**. Cancer Stat Facts: Colorectal Cancer. 2022. Available from: <https://seer.cancer.gov/statfacts/html/colorect.html>

4 **DiMatteo MR**, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. *Arch Intern Med* 2000; **160**: 2101-2107 [PMID: 10904452 DOI: 10.1001/archinte.160.14.2101]

5 **Greer JA**, Pirl WF, Park ER, Lynch TJ, Temel JS. Behavioral and psychological predictors of chemotherapy adherence in patients with advanced non-small cell lung cancer. *J Psychosom Res* 2008; **65**: 549-552 [PMID: 19027443 DOI: 10.1016/j.jpsychores.2008.03.005]

6 **Pinquart M**, Duberstein PR. Depression and cancer mortality: a meta-analysis. *Psychol Med* 2010; **40**: 1797-1810 [PMID: 20085667 DOI: 10.1017/S0033291709992285]

7 **Satin JR**, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. *Cancer* 2009; **115**: 5349-5361 [PMID: 19753617 DOI: 10.1002/cncr.24561]

8 **Baqutayan SM**. The effect of anxiety on breast cancer patients. *Indian J Psychol Med* 2012; **34**: 119-123 [PMID: 23162185 DOI: 10.4103/0253-7176.101774]

9 **Stark DP**, House A. Anxiety in cancer patients. *Br J Cancer* 2000; **83**: 1261-1267 [PMID: 11044347 DOI: 10.1054/bjoc.2000.1405]

10 **Cameron LD**, Leventhal H, Love RR. Trait anxiety, symptom perceptions, and illness-related responses among women with breast cancer in remission during a tamoxifen clinical trial. *Health Psychol* 1998; **17**: 459-469 [PMID: 9776005 DOI: 10.1037/0278-6133.17.5.459]

11 **Calderón C**, Jiménez-Fonseca P, Hernández R, Mar Muñoz MD, Mut M, Mangas-Izquierdo M, Vicente MÁ, Ramchandani A, Carmona-Bayonas A. Quality of life, coping, and psychological and physical symptoms after surgery for non-metastatic digestive tract cancer. *Surg Oncol* 2019; **31**: 26-32 [PMID: 31493647 DOI: 10.1016/j.suronc.2019.08.009]

12 **Heidari S**, Babor TF, De Castro P, Tort S, Curno M. Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use. *Res Integr Peer Rev* 2016; **1**: 2 [PMID: 29451543 DOI: 10.1186/s41073-016-0007-6]

13 **Clayton JA**, Tannenbaum C. Reporting Sex, Gender, or Both in Clinical Research? *JAMA* 2016; **316**: 1863-1864 [PMID: 27802482 DOI: 10.1001/jama.2016.16405]

14 **Maestre A**, Gonzálvez A, Carretero J. On the basis of sex and gender in healthcare. *Span J Med* 2021; **1**: 65-73[DOI: 10.24875/SJMED.M21000007]

15 **Goldzweig G**, Andritsch E, Hubert A, Walach N, Perry S, Brenner B, Baider L. How relevant is marital status and gender variables in coping with colorectal cancer? A sample of middle-aged and older cancer survivors. *Psychooncology* 2009; **18**: 866-874 [PMID: 19061195 DOI: 10.1002/pon.1499]

16 **Kalff MC**, Dijksterhuis WPM, Verhoeven RHA, Wagner AD, Lemmens VEPP, van Laarhoven HWM, Gisbertz SS, van Berge Henegouwen MI. A population-based study on gender differences in tumor and treatment characteristics and survival of curable gastroesophageal cancer. *J Clin Oncol* 2020; **38** (15\_suppl): 4550-4550 [DOI: 10.1200/JCO.2020.38.15\_suppl.4550]

17 **Dijksterhuis WPM**, Kalff MC, Wagner AD, Verhoeven RHA, Lemmens VEPP, van Oijen MGH, Gisbertz SS, van Berge Henegouwen MI, van Laarhoven HWM. Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: A Population-Based Study. *J Natl Cancer Inst* 2021; **113**: 1551-1560 [PMID: 33837791 DOI: 10.1093/jnci/djab075]

18 **Kim HW**, Kim JH, Lim BJ, Kim H, Kim H, Park JJ, Youn YH, Park H, Noh SH, Kim JW, Choi SH. Sex Disparity in Gastric Cancer: Female Sex is a Poor Prognostic Factor for Advanced Gastric Cancer. *Ann Surg Oncol* 2016; **23**: 4344-4351 [PMID: 27469120 DOI: 10.1245/s10434-016-5448-0]

19 **Yang D**, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y, Groshen S, Lenz HJ. Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. *J Gastrointest Oncol* 2011; **2**: 77-84 [PMID: 22811834 DOI: 10.3978/j.issn.2078-6891.2010.025]

20 **Najari BB**, Rink M, Li PS, Karakiewicz PI, Scherr DS, Shabsigh R, Meryn S, Schlegel PN, Shariat SF. Sex disparities in cancer mortality: the risks of being a man in the United States. *J Urol* 2013; **189**: 1470-1474 [PMID: 23206422 DOI: 10.1016/j.juro.2012.11.153]

21 **Kim J**, Ji E, Jung K, Jung IH, Park J, Lee JC, Kim JW, Hwang JH, Kim J. Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX. *J Pers Med* 2021; **11** [PMID: 33573202 DOI: 10.3390/jpm11020083]

22 **Kim HI**, Lim H, Moon A. Sex Differences in Cancer: Epidemiology, Genetics and Therapy. *Biomol Ther (Seoul)* 2018; **26**: 335-342 [PMID: 29949843 DOI: 10.4062/biomolther.2018.103]

23 **Hohla F**, Hopfinger G, Romeder F, Rinnerthaler G, Bezan A, Stättner S, Hauser-Kronberger C, Ulmer H, Greil R. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. *Int J Oncol* 2014; **44**: 319-326 [PMID: 24247204 DOI: 10.3892/ijo.2013.2176]

24 **Lambert A**, Jarlier M, Gourgou Bourgade S, Conroy T. Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial. *PLoS One* 2017; **12**: e0183288 [PMID: 28931010 DOI: 10.1371/journal.pone.0183288]

25 **Schmuck R**, Gerken M, Teegen EM, Krebs I, Klinkhammer-Schalke M, Aigner F, Pratschke J, Rau B, Benz S. Gender comparison of clinical, histopathological, therapeutic and outcome factors in 185,967 colon cancer patients. *Langenbecks Arch Surg* 2020; **405**: 71-80 [PMID: 32002628 DOI: 10.1007/s00423-019-01850-6]

26 Zentralinstitut für die kassenärztliche Versorgung in Deutschland. Available from: <https://www.zi.de/fileadmin/images/content/PDFs_alle/Beteiligungsraten_2011_Deutschland_erw.pdf>

27 **Kim SE**, Paik HY, Yoon H, Lee JE, Kim N, Sung MK. Sex- and gender-specific disparities in colorectal cancer risk. *World J Gastroenterol* 2015; **21**: 5167-5175 [PMID: 25954090 DOI: 10.3748/wjg.v21.i17.5167]

28 **Krishnan S**, Wolf JL. Colorectal cancer screening and prevention in women. *Womens Health (Lond)* 2011; **7**: 213-226 [PMID: 21410347 DOI: 10.2217/whe.11.7]

29 **Sun LM**, Liang JA, Lin CL, Sun S, Kao CH. Risk of mood disorders in patients with colorectal cancer. *J Affect Disord* 2017; **218**: 59-65 [PMID: 28458117 DOI: 10.1016/j.jad.2017.04.050]

30 **Mols F**, Schoormans D, de Hingh I, Oerlemans S, Husson O. Symptoms of anxiety and depression among colorectal cancer survivors from the population-based, longitudinal PROFILES Registry: Prevalence, predictors, and impact on quality of life. *Cancer* 2018; **124**: 2621-2628 [PMID: 29624635 DOI: 10.1002/cncr.31369]

31 **World Health Organization**. WHOQOL-HIV Instrument. Mental Health: evidence and research department of mental health and substance dependence. WHO: Geneva; 2012. Available from: <https://apps.who.int/iris/bitstream/handle/10665/77776/WHO_MSD_MER_Rev.2012.03_eng.pdf?sequence=1&isAllowed=y>

32 **Deimling GT**, Wagner LJ, Bowman KF, Sterns S, Kercher K, Kahana B. Coping among older-adult, long-term cancer survivors. *Psychooncology* 2006; **15**: 143-159 [PMID: 15880638 DOI: 10.1002/pon.931]

33 **Connor-Smith JK**, Compas BE. Coping as a moderator of relations between reactivity to interpersonal stress, health status, and internalizing problems. *Cognit Ther Res* 2004; **28**: 347-368 [DOI: 10.1023/B:COTR.0000031806.25021.d5]

34 **Subramaniam S**, Kong YC, Chinna K, Kimman M, Ho YZ, Saat N, Malik RA, Taib NA, Abdullah MM, Lim GC, Tamin NI, Woo YL, Chang KM, Goh PP, Yip CH, Bhoo-Pathy N. Health-related quality of life and psychological distress among cancer survivors in a middle-income country. *Psychooncology* 2018; **27**: 2172-2179 [PMID: 29856903 DOI: 10.1002/pon.4787]

35 **Marco DJT**, White VM. The impact of cancer type, treatment, and distress on health-related quality of life: cross-sectional findings from a study of Australian cancer patients. *Support Care Cancer* 2019; **27**: 3421-3429 [PMID: 30661203 DOI: 10.1007/s00520-018-4625-z]

36 **Tsunoda A**, Nakao K, Hiratsuka K, Yasuda N, Shibusawa M, Kusano M. Anxiety, depression and quality of life in colorectal cancer patients. *Int J Clin Oncol* 2005; **10**: 411-417 [PMID: 16369745 DOI: 10.1007/s10147-005-0524-7]

37 **Aminisani N**, Nikbakht H, Asghari Jafarabadi M, Shamshirgaran SM. Depression, anxiety, and health related quality of life among colorectal cancer survivors. *J Gastrointest Oncol* 2017; **8**: 81-88 [PMID: 28280612 DOI: 10.21037/jgo.2017.01.12]

38 **Sánchez R**, Alexander-Sierra F, Oliveros R. Relationship between quality of life and clinical status in patients with gastrointestinal cancer. *Rev Esp Enferm Dig* 2012; **104**: 584-591 [PMID: 23368650 DOI: 10.4321/S1130-01082012001100006]

39 **Oppegaard KR**, Dunn LB, Kober KM, Mackin L, Hammer MJ, Conley YP, Levine J, Miaskowski C. Gender Differences in the Use of Engagement and Disengagement Coping Strategies in Patients With Cancer Receiving Chemotherapy. *Oncol Nurs Forum* 2020; **47**: 586-594 [PMID: 32830804 DOI: 10.1188/20.ONF.586-594]

40 **von Elm E**, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* 2008; **61**: 344-349 [PMID: 18313558 DOI: 10.1016/j.jclinepi.2007.11.008]

41 **Derogatis LR**. Brief Symptom Inventory (BSI): Administration, Scoring and Procedures Manual. Minneapolis: NCS Pearson, Inc.; 1993

42 **Calderon C**, Ferrando PJ, Lorenzo-Seva U, Hernández R, Oporto-Alonso M, Jiménez-Fonseca P. Factor structure and measurement invariance of the Brief Symptom Inventory (BSI-18) in cancer patients. *Int J Clin Health Psychol* 2020; **20**: 71-80 [PMID: 32021621 DOI: 10.1016/j.ijchp.2019.12.001]

43 **Aaronson NK**, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993; **85**: 365-376 [PMID: 8433390 DOI: 10.1093/jnci/85.5.365]

44 **Calderon C**, Ferrando PJ, Lorenzo-Seva U, Ferreira E, Lee EM, Oporto-Alonso M, Obispo-Portero BM, Mihic-Góngora L, Rodríguez-González A, Jiménez-Fonseca P. Psychometric properties of the Spanish version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). *Qual Life Res* 2022; **31**: 1859-1869 [PMID: 34928470 DOI: 10.1007/s11136-021-03068-w]

45 **Watson M**, Law MG, Santos M dos, Greer S, Baruch J, Bliss J. The Mini-MAC: further development of the mental adjustment to cancer scale. *J Psychosoc Oncol* 1994; **12**: 33-46 [DOI: 10.1300/J077V12N03\_03]

46 **Calderon C**, Lorenzo-Seva U, Ferrando PJ, Gómez-Sánchez D, Ferreira E, Ciria-Suarez L, Oporto-Alonso M, Fernández-Andujar M, Jiménez-Fonseca P. Psychometric properties of Spanish version of the Mini-Mental Adjustment to Cancer Scale. *Int J Clin Health Psychol* 2021; **21**: 100185 [PMID: 33363578 DOI: 10.1016/j.ijchp.2020.06.001]

47 **Richards MA**, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. *Lancet* 1999; **353**: 1119-1126 [PMID: 10209974 DOI: 10.1016/S0140-6736(99)02143-1]

48 **Schroevers MJ**, Kraaij V, Garnefski N. Cancer patients' experience of positive and negative changes due to the illness: relationships with psychological well-being, coping, and goal reengagement. *Psychooncology* 2011; **20**: 165-172 [PMID: 20217657 DOI: 10.1002/pon.1718]

49 **Aminisani N**, Nikbakht HA, Shojaie L, Jafari E, Shamshirgaran M. Gender Differences in Psychological Distress in Patients with Colorectal Cancer and Its Correlates in the Northeast of Iran. *J Gastrointest Cancer* 2022; **53**: 245-252 [PMID: 33417199 DOI: 10.1007/s12029-020-00558-x]

50 **Gonzalez-Saenz de Tejada M**, Bilbao A, Baré M, Briones E, Sarasqueta C, Quintana JM, Escobar A. Association of social support, functional status, and psychological variables with changes in health-related quality of life outcomes in patients with colorectal cancer. *Psychooncology* 2016; **25**: 891-897 [PMID: 26582649 DOI: 10.1002/pon.4022]

51 **Braamse AM**, van Turenhout ST, Terhaar Sive Droste JS, de Groot GH, van der Hulst RW, Klemt-Kropp M, Kuiken SD, Loffeld RJ, Uiterwaal MT, Mulder CJ, Dekker J. Factors associated with anxiety and depressive symptoms in colorectal cancer survivors. *Eur J Gastroenterol Hepatol* 2016; **28**: 831-835 [PMID: 26928565 DOI: 10.1097/MEG.0000000000000615]

52 **Linden W**, Vodermaier A, Mackenzie R, Greig D. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. *J Affect Disord* 2012; **141**: 343-351 [PMID: 22727334 DOI: 10.1016/j.jad.2012.03.025]

53 **Kozak G**. Different strategies of managing neoplasia in the course of chosen cancers. *Anestezjol i Ratownictwo* 2012; **6**: 70

54 **Shapiro GK**, Mah K, de Vries F, Li M, Zimmermann C, Hales S, Rodin G. A cross-sectional gender-sensitive analysis of depressive symptoms in patients with advanced cancer. *Palliat Med* 2020; **34**: 1436-1446 [PMID: 32781931 DOI: 10.1177/0269216320947961]

55 **Trinquinato I**, Marques da Silva R, Ticona Benavente SB, Antonietti CC, Siqueira Costa Calache AL. Gender differences in the perception of quality of life of patients with colorectal cancer. *Invest Educ Enferm* 2017; **35**: 320-329 [PMID: 29767912 DOI: 10.17533/udea.iee.v35n3a08]

56 **Czerw A**, Religioni U, Banaś T. Perception of cancer in patients diagnosed with the most common gastrointestinal cancers. *BMC Palliat Care* 2020; **19**: 144 [PMID: 32943037 DOI: 10.1186/s12904-020-00650-w]

57 **Hansen IO**, Jess P. Possible better long-term survival in left versus right-sided colon cancer - a systematic review. *Dan Med J* 2012; **59**: A4444 [PMID: 22677242]

58 **Benedix F**, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H; Colon/Rectum Carcinomas (Primary Tumor) Study Group. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. *Dis Colon Rectum* 2010; **53**: 57-64 [PMID: 20010352 DOI: 10.1007/DCR.0b013e3181c703a4]

59 **Holch JW**, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. *Eur J Cancer* 2017; **70**: 87-98 [PMID: 27907852 DOI: 10.1016/j.ejca.2016.10.007]

60 **Majek O**, Gondos A, Jansen L, Emrich K, Holleczek B, Katalinic A, Nennecke A, Eberle A, Brenner H; GEKID Cancer Survival Working Group. Sex differences in colorectal cancer survival: population-based analysis of 164,996 colorectal cancer patients in Germany. *PLoS One* 2013; **8**: e68077 [PMID: 23861851 DOI: 10.1371/journal.pone.0068077]

61 **Franceschi S**, Gallus S, Talamini R, Tavani A, Negri E, La Vecchia C. Menopause and colorectal cancer. *Br J Cancer* 2000; **82**: 1860-1862 [PMID: 10839302 DOI: 10.1054/bjoc.1999.1084]

62 **Mueller F**, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl S, Froehlich TK, Largiader CR, Joerger M. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. *Cancer Chemother Pharmacol* 2013; **71**: 361-370 [PMID: 23139054 DOI: 10.1007/s00280-012-2018-4]

63 **Berg AK**, Buckner JC, Galanis E, Jaeckle KA, Ames MM, Reid JM. Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure. *J Clin Pharmacol* 2015; **55**: 1303-1312 [PMID: 25975718 DOI: 10.1002/jcph.543]

64 **Klein CE**, Gupta E, Reid JM, Atherton PJ, Sloan JA, Pitot HC, Ratain MJ, Kastrissios H. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. *Clin Pharmacol Ther* 2002; **72**: 638-647 [PMID: 12496745 DOI: 10.1067/mcp.2002.129502]

65 **Wu H**, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris HA 3rd, Zamboni WC. Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors. *Eur J Clin Pharmacol* 2013; **69**: 2073-2081 [PMID: 23989300 DOI: 10.1007/s00228-013-1580-y]

66 **Cristina V**, Mahachie J, Mauer M, Buclin T, Van Cutsem E, Roth A, Wagner AD. Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group. *JAMA Oncol* 2018; **4**: 1003-1006 [PMID: 29800044 DOI: 10.1001/jamaoncol.2018.1080]

67 **Czerw AI**, Religioni U, Deptała A, Walewska-Zielecka B. Assessment of pain, acceptance of illness, adjustment to life with cancer, and coping strategies in colorectal cancer patients. *Prz Gastroenterol* 2016; **11**: 96-103 [PMID: 27350836 DOI: 10.5114/pg.2015.52561]

68 **Hoyt MA**, Rubin LR. Gender representation of cancer patients in medical treatment and psychosocial survivorship research: changes over three decades. *Cancer* 2012; **118**: 4824-4832 [PMID: 22294480 DOI: 10.1002/cncr.27432]

**Footnotes**

**Institutional review board statement:** The study was approved by the Research Ethics Committee of the Principality of Asturias (May 17, 2019) and by the Spanish Agency of Medicines and Medical Devices (Identification code: L34LM-MM2GH-Y925U RJDHQ). The study has been performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. This study is an observational, non-interventionist trial.

**Informed consent statement:** Signed informed consent was obtained from all patients.

**Conflict-of-interest statement:** Dr. Pacheco-Barcia reports grants from FSEOM and grants from Astra Zeneca during the conduct of the study; other from Eisai, other from Merck, other from Eli Lilly, other from Advanced accelerator applications, a Novartis company, grants from FSEOM and Merck, other from Roche, other from Eli Lilly, other from Bristol-Myers Squibb, other from Merck, other from Amgen, other from Merck Sharp and Dhome, other from Nutricia, other from Roche, other from Bayer, other from Amgen, other from Esteve, other from Eli Lilly, other from Roche, other from Bristol-Myers Squibb, grants from Ayuda Clínico Formativa AECC 2020, grants from FSEOM, outside the submitted work.

**Data sharing statement:** This database is available through a centralized web platform: www.neoetic.es. The code is available upon request to the authors. Code availability: Patients are identified by an encrypted code known only to the local researcher. The analysis code is available upon request to the authors.

**STROBE statement:** The study was undertaken according to the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author’s Membership in Professional Societies:** Spanish Society of Medical Oncology; and European Society of Medical Oncology, No. 390979.

**Peer-review started:** April 25, 2022

**First decision:** May 11, 2022

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** Spain

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A, A

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Gao W, China; Rwegerera GM, Botswana; Scurtu RR, Romania; Yu T, China **S-Editor:** Gong ZM **L-Editor:** Filipodia **P-Editor:** Gong ZM

**Figure Legends**



**Figure 1 Scores obtained on the Brief Symptom Inventory-18, European** **Organization** **for** **Research** **and** **Treatment** **of** **Cancer** **Quality** **of** **Life** **Questionnaire for men *vs* women and for patients with colorectal *vs* digestive (non-colorectal) cancer.** BSI: Brief Symptom Inventory; EORTC: European Organization for Research and Treatment of Cancer; RW: Raw.



**Figure 2 Scores obtained on the Mini-Mental Adjustment to Cancer scales for men *vs* women and for patients with colorectal *vs* digestive (non-colorectal) cancer.** MAC: Mini-Mental Adjustment to Cancer; RS: Raw score.

**Table 1 Patients’ baseline characteristics, *n* = 203**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Characteristic** | **Total** | **Colorectal, *n* = 101** | **Non-colorectal digestive cancer, *n* = 102** | ***P* value** | **λ** |
| ***n*** | **%** | ***n*** | **%** | ***n*** | **%** |
| Sex |  |  |  |  |  |  | 0.622 | 0.026 |
| Men | 115 | 56.7 | 60 | 59.4 | 55 | 53.9 |  |  |
| Women | 88 | 43.3 | 41 | 40.6 | 47 | 46.1 |  |  |
| Age |  |  |  |  |  |  | 0.028 | 0.081 |
| ≤ 65 yr | 85 | 41.9 | 50 | 49.5 | 35 | 34.3 |  |  |
| > 65 yr | 118 | 59.1 | 51 | 50.5 | 67 | 65.7 |  |  |
| Number of Elixhauser comorbidities (%) |  |  |  |  |  |  | 0.344 | 0.033 |
| ≤ 4 | 81 | 39.9 | 37 | 36.6 | 44 | 43.1 |  |  |
| > 4 | 122 | 60.1 | 64 | 63.4 | 58 | 56.9 |  |  |
| ECOG |  |  |  |  |  |  | 0.029 | 0.086 |
| 0 | 56 | 27.6 | 35 | 34.7 | 21 | 20.6 |  |  |
| 1 | 138 | 68.0 | 62 | 61.4 | 76 | 74.5 |  |  |
| 2 | 9 | 4.4 | 4 | 4.0 | 5 | 4.9 |  |  |
| Marital status |  |  |  |  |  |  | 0.883 | 0.001 |
| Married/partnered | 167 | 86.6 | 87 | 86.2 | 92 | 87.0 |  |  |
| Not partnered | 36 | 13.4 | 24 | 13.8 | 24 | 13.0 |  |  |
| Children |  |  |  |  |  |  | 0.370 | 0.029 |
| Do not have children | 35 | 17.2 | 15 | 14.9 | 20 | 19.6 |  |  |
| Have children | 168 | 82.8 | 86 | 85.1 | 82 | 81.4 |  |  |
| Educational level |  |  |  |  |  |  | 0.521 | 0.010 |
| Primary  | 112 | 55.2 | 58 | 57.4 | 54 | 52.9 |  |  |
| High school or higher  | 91 | 44.8 | 43 | 42.6 | 48 | 47.1 |  |  |
| Histology |  |  |  |  |  |  | 0.001 | 0.129 |
| Adenocarcinoma | 180 | 88.7 | 98 | 97.0 | 82 | 80.4 |  |  |
| Others | 23 | 11.3 | 3 | 3.0 | 20 | 19.6 |  |  |
| Metastasis |  |  |  |  |  |  | 0.001 | 0.218 |
| Locally advanced  | 32 | 15.8 | 1 | 1.0 | 31 | 30.4 |  |  |
| Metastatic disease  | 171 | 84.2 | 100 | 99.0 | 71 | 69.6 |  |  |
| Biomarker |  |  |  |  |  |  | 0.001 | 0.196 |
| No | 161 | 79.3 | 66 | 65.3 | 95 | 93.1 |  |  |
| Yes | 42 | 20.7 | 35 | 34.7 | 7 | 6.9 |  |  |
| Estimated survival  |  |  |  |  |  |  | 0.001 | 0.776 |
| < 18 mo | 108 | 53.2 | 14 | 13.9 | 94 | 92.2 |  |  |
| ≥ 18 mo | 95 | 4.8 | 87 | 86.1 | 8 | 7.8 |  |  |
| Treatment modality |  |  |  |  |  |  | 0.001 | 0.339 |
| Chemotherapy | 139 | 68.5 | 45 | 44.6 | 94 | 92.2 |  |  |
| Combined  | 64 | 31.5 | 56 | 54.4 | 8 | 7.8 |  |  |

ECOG: Eastern Cooperative Oncology Group.

**Table 2 Univariate general linear model for predicting psychological distress, quality of life, and coping strategies by tumor and sex**

|  |  |  |  |
| --- | --- | --- | --- |
| **Scales** | **Colorectal cancer, *n* = 101** | **Non-colorectal digestive cancer, *n* = 102** | **ANOVA results, *F*** |
| **Men, mean (SD)** | **Women, mean (SD)** | **Men, mean (SD)** | **Women, mean (SD)** | **Tumor × sex** | **Tumor** | **Sex** |
| Psych. distress (BSI)1 |  |  |  |  |  |  |  |
| Somatization  | 62.0 (6.3) | 64.1 (8.0) | 63.9 (6.7) | 66.3 (8.1) | 0.021 | 3.963 | 5.044 |
| Depression | 60.3 (6.6) | 65.0 (6.6) | 60.1 (5.5) | 62.9 (7.5) | 0.923 | 1.423 | 15.747 |
| Anxiety  | 61.9 (7.8) | 65.8 (8.3) | 61.9 (6.8) | 66.0 (8.3) | 0.030 | 0.011 | 12.818 |
| Quality of life (EORTC-QLQ-C30)2 |  |  |  |  |  |  |  |
| Functional scale | 79.6 (17.4) | 62.3 (23.0) | 70.8 (22.6) | 60.8 (24.0) | 1.427 | 2.781 | 19.697 |
| Symptom scale | 24.4 (22.9) | 29.8 (19.4) | 28.6 (17.8) | 40.0 (22.1) | 1.044 | 6.067 | 8.154 |
| Health status scale | 67.6 (22.6) | 53.7 (27.9) | 51.9 (23.5) | 55.1 (32.8) | 5.185 | 3.547 | 2.059 |
| Coping with cancer (M-MAC)2 |  |  |  |  |  |  |  |
| Helplessness | 24.0 (22.9) | 25.0 (21.9) | 25.9 (22.8) | 28.6 (25.6) | 0.069 | 0.696 | 0.288 |
| Anxious preoccupation | 46.2 (24.4) | 51.4 (18.8) | 43.8 (19.0) | 54.4 (23.6) | 0.800 | 0.008 | 6.722 |
| Positive attitude | 83.4 (16.5) | 76.8 (18.1) | 79.2 (15.8) | 74.9 (22.9) | 0.186 | 1.364 | 4.389 |
| Cognitive avoidance | 66.6 (27.3) | 60.6 (21.6) | 64.3 (24.5) | 60.2 (27.1) | 0.036 | 0.192 | 1.758 |

1T score.

2Scale from 0 to 100.

ANOVA: Analysis of variance; BSI: Brief Symptom Inventory; EORTC-QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; M-MAC: Mini-Mental Adjustment to Cancer; SD: Standard deviation.